In vivo effects of zoledronic acid on lymphocyte subpopulations in patients with primary osteoporosis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021796

Enrollment

Unknown

Registered

2019-03-10

Start date

2015-01-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary osteoporosis

Interventions

Case series:zoledronic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who had been diagnosed with primary osteoporosis; serum calcium and phosphorus in the normal level; creatinine clearance >35ml/min,

Exclusion criteria

Exclusion criteria: Administration of amino-bisphosphonates before; With serious complications including the liver or kidney disease; cancer or acute infections.

Design outcomes

Primary

Measure	Time frame
lymphocyte subpopulations;BMD;?isomer of the C-terminal telopeptide of;N-terminal midfragmet of osteocalcin;Parathyroid hormone;	—

Countries

China

Contacts

Public ContactMin Cui

Jinan Central Hospital affiliated to Shandong University

cuiminsd@163.com+86 0531-85695150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026